|Day Low/High||5.68 / 6.21|
|52 Wk Low/High||4.82 / 26.96|
I'm looking at a possible inverse head and shoulders forming on many cannabis charts.
beat (and share price +6%) should really help our recent buy as Canopy Growth represents 7.4% of the ETF: $CGC 3Q NET REV. C$141M; EST. C$138M$CGC 3Q ADJ EBITDA (C$67M); EST. (C$65M) initial stock reaction: +10% ¿¿ #cannabis ¿https://t.co/LgDhJDB0sn...
After being weak recently, Canadian cannabis stocks ( and ) are up by nearly +10% today. In serving the Canadian pot market, these companies are disadvantaged vs. the U.S. multi state operators (held in ). I expect some quick "ketchup" by the MSOS c...
Leading advisors pick four favorite cannabis purveyors, two marijuana ETFs and one ancillary tobacco segment firm.
ETF MSOS is seen as an opportunity to get exposure to stocks that are not yet U.S. listed.
I'm willing to take a small shot on a September call spread and ride through earnings.
nikogeorge dougie kass • 15 minutes ago I see investments in MSOs (multi-state operators) (i.e. , , , ) as the ones that benefit while the wait for legislation grinds into existence. As they are the ones that have the state licenses, which are limit...
Viridian Capital believes Michigan could be the third biggest state for cannabis sales behind California and Colorado.
A bit of good news from Pernod Ricard came across my screen, so let's see if we can have a toast to other, similar liquor brands.
Leading advisors offer their favorite ideas for investors looking for exposure to the growing marijuana market.
Seasonally adjusted data, always suspect, has never meant less than now, when there really is no historical comparison -- to anything
A look at STZ after its latest earnings report.
This stock can be bought for a trade today, but only by someone who watches their positions closely and acts aggressively.
You can listen to the haters on Twitter and Reddit, or you can see what I've been doing since 1979: trying to help the average Joe make some money.
More competition at lower prices will make it harder to be profitable.
One possible outcome: The party ends relatively soon for some of the more speculative names, while other high-multiple stocks remain strong until inflation and the Fed become issues.
Traders should look to buy available weakness into the $12-$11 area.
They really do not have very high hopes for the short to medium term future. Yet, the market buys their news.
The Russell 2000 has now soared 16% year to date, nearly twice the Nasdaq Composite's 8.5% move.
Shares of the cannabis stock have recently strengthened.
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Georgia's election results have given the industry a big green light, meaning positive moves are expected out of cannabis stocks.
Let's take a fresh look at the charts and indicators.